JP2008536487A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536487A5
JP2008536487A5 JP2008501411A JP2008501411A JP2008536487A5 JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5 JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5
Authority
JP
Japan
Prior art keywords
cells
activated
tumor cell
atcp
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008501411A
Other languages
English (en)
Japanese (ja)
Other versions
JP5663135B2 (ja
JP2008536487A (ja
Filing date
Publication date
Priority claimed from GB0505508A external-priority patent/GB0505508D0/en
Priority claimed from GB0514288A external-priority patent/GB0514288D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000960 external-priority patent/WO2006097743A2/en
Publication of JP2008536487A publication Critical patent/JP2008536487A/ja
Publication of JP2008536487A5 publication Critical patent/JP2008536487A5/ja
Application granted granted Critical
Publication of JP5663135B2 publication Critical patent/JP5663135B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008501411A 2005-03-17 2006-03-16 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法 Expired - Fee Related JP5663135B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0505508A GB0505508D0 (en) 2005-03-17 2005-03-17 Method
GB0505508.2 2005-03-17
GB0514288.0 2005-07-12
GB0514288A GB0514288D0 (en) 2005-07-12 2005-07-12 Method
PCT/GB2006/000960 WO2006097743A2 (en) 2005-03-17 2006-03-16 Method for actvating natural killer cells by tumor cell preparation in vitro

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012224042A Division JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Division JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法

Publications (3)

Publication Number Publication Date
JP2008536487A JP2008536487A (ja) 2008-09-11
JP2008536487A5 true JP2008536487A5 (https=) 2009-03-12
JP5663135B2 JP5663135B2 (ja) 2015-02-04

Family

ID=36992099

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008501411A Expired - Fee Related JP5663135B2 (ja) 2005-03-17 2006-03-16 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法
JP2012224042A Expired - Lifetime JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Withdrawn JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012224042A Expired - Lifetime JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Withdrawn JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってinvitroでナチュラルキラー細胞を活性化させるための方法

Country Status (9)

Country Link
US (3) US8257970B2 (https=)
EP (2) EP1863905B1 (https=)
JP (3) JP5663135B2 (https=)
AU (1) AU2006224313B2 (https=)
CA (1) CA2601197C (https=)
DK (1) DK1863905T3 (https=)
ES (1) ES2566335T3 (https=)
PL (1) PL1863905T3 (https=)
WO (1) WO2006097743A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit
CN102575230A (zh) * 2009-07-10 2012-07-11 马克·洛戴尔 活化的nk细胞的经保存的组合物及其使用方法
KR102246369B1 (ko) 2011-11-30 2021-04-29 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
WO2013132256A1 (en) 2012-03-07 2013-09-12 Ucl Business Plc Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
CN104321425B (zh) * 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
US9745551B2 (en) 2012-07-12 2017-08-29 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
BR112017004270B1 (pt) * 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
US10758567B2 (en) 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
WO2018170309A1 (en) * 2017-03-15 2018-09-20 Immune Ventures, Llc In vivo priming of natural killer cells
ES2871100T3 (es) * 2015-12-07 2021-10-28 Immune Ventures LLC Cebado in vivo de linfocitos citolíticos naturales
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) * 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Nk細胞を含む細胞集団の製造方法
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
KR20250118299A (ko) * 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) * 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell

Similar Documents

Publication Publication Date Title
JP2008536487A5 (https=)
Ginckels et al. Oxidative stress and inflammation in cardiovascular diseases and cancer: role of non-coding RNAs
Gkikas et al. The role of mitophagy in innate immunity
Bailly et al. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Park et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Nehrbas et al. Extracellular vesicles and chemotherapy resistance in the AML microenvironment
Showel et al. Advances in treating acute myeloid leukemia
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
MX2010010726A (es) Composicion de estilizado de cabello.
Wang et al. Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool
BRPI0612612A2 (pt) compàsitos de celulose reconstituÍdos por lÍquido iânico como matrizes de suporte sàlido
JP2016501013A5 (https=)
JP2008519047A5 (https=)
NZ599825A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
JP2009232853A5 (https=)
Li et al. ADAR1 attenuates allogeneic graft rejection by suppressing miR‐21 biogenesis in macrophages and promoting M2 polarization
Kanat et al. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer
Guo et al. Betaine effects on morphology, proliferation, and p53-induced apoptosis of hela cervical carcinoma cells in vitro
SG149875A1 (en) Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds
WO2017087947A3 (en) Method of treatment of follicular lymphoma with a btk inhibitor
Ziko et al. Mechanical Stress Promotes Cisplatin‐Induced Hepatocellular Carcinoma Cell Death
Huart et al. Could protons and carbon ions be the silver bullets against pancreatic cancer?
Kim et al. A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells
WO2017200492A1 (en) Method of treating cancer
Liang et al. Immune cells in systemic lupus erythematosus: biology and traditional Chinese medicine therapy